Guardant Health ( (GH) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Guardant Health’s stock has climbed following their announcement of a partnership with the Abu Dhabi Public Health Center to launch a non-invasive blood-based colorectal cancer screening program. This strategic expansion, facilitated by Hikma Pharmaceuticals and the M42 healthcare system, has generated positive market sentiment. The stock’s upward movement is also supported by favorable price target adjustments, driven by the granting of coverage for Guardant Reveal by the MolDX administrator. These developments highlight the company’s expanding role in global cancer diagnostics.
More about Guardant Health
YTD Price Performance: 49.98%
Average Trading Volume: 2,109,302
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $5.96B
For further insights into GH stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.